# MonumenTAL-2 (NCT05050097)

> A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05050097
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Talquetamab; Carfilzomib; Daratumumab SC; Lenalidomide; Pomalidomide
- Enrollment: 166
- Primary outcome: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Primary outcome: Number of Participants with AEs by Severity
- Primary outcome: Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters
- Primary outcome: Number of Participants with Dose Limiting Toxicity (DLT)

## Commentary we found

- YouTube: 9
- Podcasts: 5
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=monumental-2-nct05050097

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05050097", "email": "<work email>"}; the inbox owner confirms by the emailed link.